performed a retrospective review to examine sex differences in irAEs in all patients with metastatic melanoma, or non-small-cell lung cancer treated with PD-1 and PD-L1 inhibitors, and they discovered that females had a higher risk of irAEs than males did for both the conditions (61). This evidence concerns the gene PDCD1 and metastatic melanoma.